75 results on '"Holbrechts S"'
Search Results
2. 115P BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
- Author
-
Martins-Branco, D., Franzoi, M.A., Nader-Marta, G., Gombos, A., Vanhaudenarde, V., De Maio D'Esposito, E., Goncalves, A., Clatot, F., Holbrechts, S., Cheymol, C., Borcoman, E., Denys, H., Gligorov, J., Kindt, N., Abu-Serieh, B., Paesmans, M., Awada, A.H., and Kotecki, N.
- Published
- 2023
- Full Text
- View/download PDF
3. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer
- Author
-
Berghmans, T., Van Houtte, P., Paesmans, M., Giner, V., Lecomte, J., Koumakis, G., Richez, M., Holbrechts, S., Roelandts, M., Meert, A.P., Alard, S., Leclercq, N., and Sculier, J.P.
- Published
- 2009
- Full Text
- View/download PDF
4. P-276 Sex and regorafenib toxicity in refractory colorectal cancer: A safety analysis of the RegARd-C trial
- Author
-
Vandeputte, C., primary, Bregni, G., additional, Paraskevas, G., additional, Guiot, T., additional, Kehagias, P., additional, Deleporte, A., additional, Geboes, K., additional, Delaunoit, T., additional, Demolin, G., additional, Peeters, M., additional, D'Hondt, L., additional, Janssens, J., additional, Carrasco, J., additional, Holbrechts, S., additional, Goeminne, J., additional, Vergauwe, P., additional, Van Laethem, J., additional, Flamen, P., additional, Hendlisz, A., additional, and Sclafani, F., additional
- Published
- 2021
- Full Text
- View/download PDF
5. Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review
- Author
-
Tota, Vito, Dagonnier, Marie, Wery, Didier, Binet, Laure, Nagy, Nathalie, Durieux, Valérie, Diaz, Marie, Elosegi, Jose Antonio, Holbrechts, S., Tota, Vito, Dagonnier, Marie, Wery, Didier, Binet, Laure, Nagy, Nathalie, Durieux, Valérie, Diaz, Marie, Elosegi, Jose Antonio, and Holbrechts, S.
- Abstract
Immune checkpoint inhibitors (ICI) improve the prognosis of patients with advanced non-small cell lung cancer. However, clinicians should be aware of potentially life-threatening immune-related adverse events (irAEs). We report a case of a 67-year-old man with lung adenocarcinoma who developed an acute ischemic stroke after the second administration of pembrolizumab. The patient benefited from thrombolysis and mechanical thrombectomy with improved neurological outcome. An anti-phospholipid syndrome (APS) was diagnosed. Simultaneously, he developed a grade IV autoimmune hepatitis. Both manifestations were considered irAEs and the ICI treatment was discontinued. Steroids were initiated resulting in irAEs resolution. Remarkably, the patient achieved a complete oncological response and persistent remission after one year follow-up despite early discontinuation of pembrolizumab. Of note, APS is rarely reported as irAE. To our knowledge, this is the first case reported in the context of lung cancer. A systematic review of the literature is provided., SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2021
6. Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice
- Author
-
Bregni, Giacomo, Akin Telli, Tugba, Camera, Silvia, Deleporte, Amélie, Moretti, Luigi, Bali, A.M., Liberale, Gabriel, Holbrechts, S., Hendlisz, Alain, Sclafani, Francesco, Bregni, Giacomo, Akin Telli, Tugba, Camera, Silvia, Deleporte, Amélie, Moretti, Luigi, Bali, A.M., Liberale, Gabriel, Holbrechts, S., Hendlisz, Alain, and Sclafani, Francesco
- Abstract
While adjuvant chemotherapy is an established treatment for pathological stage II and especially stage III colon cancer, its role in the multimodal management of rectal cancer remains controversial. As a result, there is substantial variation in the use of this treatment in clinical practice. Even among centres and physicians who consider adjuvant chemotherapy as a standard treatment, notable heterogeneity exists with regard to patient selection criteria and chemotherapy regimens. The controversy around this topic is confirmed by the lack of full consensus among national and international clinical guidelines. While most of the clinical trials do not support the contention that adjuvant chemotherapy may improve survival outcomes if pre-operative (chemo)radiotherapy is also given, these suffer from many limitations that preclude drawing definitive conclusions. Nevertheless, in the era of evidence-based medicine, physicians should be guided by the available data and refrain from extrapolating results of adjuvant colon cancer trials to inform treatment decisions for rectal cancer. Patients should be informed of the evidence gap, be given the opportunity to carefully discuss pros and cons of all the possible management options and be empowered in the decision making. In this article we review the available evidence on adjuvant chemotherapy for rectal cancer and propose a risk-adapted decisional algorithm that largely relies on informed patient preferences., SCOPUS: re.j, info:eu-repo/semantics/published
- Published
- 2020
7. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial
- Author
-
Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Michel, Marechal, Raphaël, Delaunoit, Thierry, Goemine, J.C., Laurent, Stéphanie, Holbrechts, S., Paesmans, Marianne, Van Laethem, Jean-Luc, Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Michel, Marechal, Raphaël, Delaunoit, Thierry, Goemine, J.C., Laurent, Stéphanie, Holbrechts, S., Paesmans, Marianne, and Van Laethem, Jean-Luc
- Abstract
Background: There is a high unmet clinical need for treatments of advanced/metastatic biliary tract cancers after progression on first-line chemotherapy. Regorafenib has demonstrated efficacy in some gastrointestinal tumors that progress on standard therapies. Patients and methods: REACHIN was a multicenter, double-blind, placebo-controlled, randomized phase II study designed to evaluate the safety and efficacy of regorafenib in patients with nonresectable/metastatic biliary tract cancer that progressed after gemcitabine/platinum chemotherapy. Patients were randomly assigned 1: 1 to best supportive care plus either regorafenib 160 mg once daily 3 weeks on/1 week off or placebo until progression or unacceptable toxicity. No crossover was allowed. The primary objective was progression-free survival (PFS). Secondary objectives were response rate, overall survival, and translational analysis. Results: Sixty-six patients with intrahepatic (n = 42), perihilar (n = 6), or extrahepatic (n = 9) cholangiocarcinoma, or gallbladder carcinoma (n = 9) were randomized, 33 to each treatment group (33 per group). At a median follow-up of 24 months, all patients had progressed and six patients were alive. Median treatment duration was 11.0 weeks [95% confidence interval (CI): 6.0–15.9] in the regorafenib group and 6.3 weeks (95% CI: 3.9–7.0) in the placebo group (P = 0.002). Fourteen of 33 patients (42%) in the regorafenib group had a dose reduction. Stable disease rates were 74% (95% CI: 59–90) in the regorafenib group and 34% with placebo (95% CI: 18–51; P = 0.002). Median PFS in the regorafenib group was 3.0 months (95% CI: 2.3–4.9) and 1.5 months (95% CI: 1.2–2.0) in the placebo group (hazard ratio 0.49; 95% CI: 0.29–0.81; P = 0.004) and median overall survival was 5.3 months (95% CI: 2.7–10.5) and 5.1 months (95% CI: 3.0–6.4), respectively (P = 0.28). There were no unexpected/new safety signals. Conclusion: Regorafenib significantly improved PFS and tumor control in patients wit, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2020
8. Adjuvant chemotherapy for rectal cancer: Current evidence and recommendations for clinical practice
- Author
-
Bregni, G., primary, Akin Telli, T., additional, Camera, S., additional, Deleporte, A., additional, Moretti, L., additional, Bali, A.M., additional, Liberale, G., additional, Holbrechts, S., additional, Hendlisz, A., additional, and Sclafani, F., additional
- Published
- 2020
- Full Text
- View/download PDF
9. The rol of direct oral anticoagulants in the management of cancer-associated thrombosis
- Author
-
Awada, A, Baurain, JF, Clement, Paul, Hainaut, P, Holbrechts, S, Jochmans, K, Mathieux, V, Mebis, J, Strijbos, M, Vulsteke, C, Vanassche, T, and Verhamme, P
- Abstract
ispartof: Belgian Journal of Hematology vol:10 issue:4 pages:169-176 status: published
- Published
- 2019
10. Screening for occult cancer in patients with unprovoked venous thromboembolism: belgian expert guidance
- Author
-
Clement, Paul, Awada, A, Baurain, JF, Hainaut, P, Holbrechts, S, Jochmans, K, Mathieux, V, Mebis, J, Strijbos, M, Vulsteke, C, Vanassche, T, and Verhamme, P
- Abstract
ispartof: Belgian Journal of Medical Oncology vol:12 pages:326-329 status: published
- Published
- 2018
11. Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors
- Author
-
Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Michel, Marechal, Raphaël, Delaunoit, Thierry, Goeminne, Jean Charles, Laurent, Stéphanie, Holbrechts, S., Paesmans, Marianne, Van Laethem, Jean-Luc, Demols, Anne, Borbath, Ivan, Van Den Eynde, Marc, Houbiers, Ghislain, Peeters, Michel, Marechal, Raphaël, Delaunoit, Thierry, Goeminne, Jean Charles, Laurent, Stéphanie, Holbrechts, S., Paesmans, Marianne, and Van Laethem, Jean-Luc
- Abstract
SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2019
12. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: A post hoc analysis of two non-randomized phase II trials
- Author
-
Charette, Nicolas, Vandeputte, Caroline, Ameye, Lieveke, Van Bogaert, Camille, Krygier, Jonathan, Guiot, Thomas, Deleporte, Amélie, Delaunoit, Thierry, Geboes, K., Van Laethem, Jean-Luc, Peeters, Michel, Demolin, Gauthier, Holbrechts, S., Flamen, Patrick, Paesmans, Marianne, Hendlisz, Alain, Charette, Nicolas, Vandeputte, Caroline, Ameye, Lieveke, Van Bogaert, Camille, Krygier, Jonathan, Guiot, Thomas, Deleporte, Amélie, Delaunoit, Thierry, Geboes, K., Van Laethem, Jean-Luc, Peeters, Michel, Demolin, Gauthier, Holbrechts, S., Flamen, Patrick, Paesmans, Marianne, and Hendlisz, Alain
- Abstract
Background: The prognostic value of body composition in cancer patients has been widely studied during the last decade. The main finding of these studies is that sarcopenia, or skeletal muscle depletion, assessed by CT imaging correlates with a reduced overall survival (OS). By contrast, the prognostic value of fat mass remains ill-defined. This study aims to analyze the influence of body composition including both muscle mass and adipose tissue on OS in a homogeneous population of advanced colorectal cancer (CRC) patients. Methods: Among 235 patients with chemorefractory advanced CRC included in the SoMore and RegARd-C trials, body composition was assessed in 217 patients on baseline CT images. The relationship between body composition (sarcopenia, muscle density, subcutaneous and visceral fat index and density), body mass index (BMI) and OS were evaluated. Results: Patients with a higher BMI had a better OS (≥30 versus < 30, HR: 0.50; 0.33-0.76). Those with low muscle index and muscle density had an increased mortality (HR: 2.06; 1.45-2.93 and HR: 1.54; 1.09-2.18, respectively). Likewise, low subcutaneous and visceral fat index were associated with an increased risk of dying (HR: 1.63; 1.23-2.17 and 1.48; 1.09-2.02 respectively), as were a high subcutaneous and visceral adipose tissue density (HR: 1.93; 1.44-2.57 and 2.40; 1.79-3.20 respectively). In multivariate analysis, a high visceral fat density was the main predictor of poor survival. Conclusions: Our results confirm the protective role of obesity in CRC patients at an advanced stage, as well as the negative prognostic impact of muscle depletion on survival. More importantly, our data show for the first time that visceral adipose tissue density is an important prognostic factor in metastatic CRC. Trial registration: NCT01290926, 07/02/2011 and NCT01929616, 28/08/2013., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2019
13. Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors
- Author
-
Demols, A., primary, Borbath, I., additional, Van den Eynde, M., additional, Houbiers, G., additional, Peeters, M., additional, Marechal, R., additional, Delaunoit, T., additional, Goeminne, J., additional, Laurent, S., additional, Holbrechts, S., additional, Paesmans, M., additional, and Van Laethem, J., additional
- Published
- 2019
- Full Text
- View/download PDF
14. Unusual presentation of a hepatocellular carcinoma as a potential late side effect of radiotherapy in a patient treated for Wilms tumor in childhood
- Author
-
Repullo, Deborah, Diaz, Marie, Holbrechts, S., Gomez-Galdon, Maria, Van Gestel, Dirk, Bohlok, Ali, Liberale, Gabriel, Donckier De Donceel, Vincent, Repullo, Deborah, Diaz, Marie, Holbrechts, S., Gomez-Galdon, Maria, Van Gestel, Dirk, Bohlok, Ali, Liberale, Gabriel, and Donckier De Donceel, Vincent
- Abstract
Background: The development of a second primary tumor is a potential late side effect of radiotherapy. Particularly, an increased risk of secondary cancers, mostly of digestive or breast origin, has been observed in patients treated with high-dose radiotherapy for Wilms tumor (WT) in childhood. However, hepatocellular carcinoma (HCC) has been very rarely described as a potentially radiotherapy-induced tumor. We describe the case of a patient with an aggressive HCC 50 years after the treatment of a WT. Case presentation: A 49-year old man, treated at the age of 6 weeks for a right WT by a right nephrectomy and adjuvant radiotherapy, presented with a right abdominal mass. Imaging demonstrated a 100-mm tumor invading the inferior segment of the right liver, the right colon and the right psoas muscle. The patient had no previous history of liver disease, nor of alcohol consumption, and hepatitis serologies were negatives. Biopsy demonstrated a poorly differentiated tumor of unknown origin. A panel of tumor markers was negative. Explorative surgery has been performed allowing en bloc R0 tumor resection, including resection of segments VI and VII of the liver, right hemicolectomy and resection of the anterior sheet of the right psoas muscle. Pathological examination revealed a poorly differentiated HCC. No signs of cirrhosis or chronic liver disease were observed in the non-tumor liver. Twenty weeks after surgery, the patient developed a multifocal tumor recurrence that was treated with intra-arterial 90Yttrium radioembolization. Conclusion: In this case, the absence of risk factors for HCC, such as cirrhosis, viral hepatitis and chronic liver disease, highly suggests the development of HCC to be related to previous high-dose radiation therapy given for a right WT to a field involving the inferior part of the liver. This observation shows radiotherapy to/near the liver, particularly in childhood, to be a potential risk factor for HCC, stressing the need for a long-term sp, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2018
15. Guidance for the prevention and treatment of venous thromboembolism in cancer patients
- Author
-
Awada, Ahmad, Baurain, Jean-François, Clement, Paul, Hainaut, P, Holbrechts, S., Hougardy, Jean-Michel, Jochmans, Kristin, Mathieux, V, Mebis, J, Strijbos, M, Vulsteke, C, Verhamme, P, Hematology, Reproductive immunology and implantation, and Clinical sciences
- Subjects
trombose - Abstract
Venous thrombosis is a common complication in cancer patients and thromboembolism is the second most common cause of death. Several practice guidelines provide recommendations for the management of cancer-associated thrombosis. However, these guidelines do not suffi ciently cover commonly encountered clinical challenges. With this expert panel, consisting of medical oncologists, haematologists, internists and thrombosis specialists, we aimed to develop a practical Belgian guidance for adequate prevention and treatment of cancer-associated thrombosis that covered several challenging situations encountered in daily clinic. This paper discusses the following topics: type and treatment duration of anticoagulant therapy, recurrent VTE despite anticoagulation, anticoagulation in case of renal impairment, liver disease and thrombocytopenia, the role of anti-Xa monitoring, central venous catheter-associated thrombosis, the position of direct oral anticoagulants and thromboprophylaxis, both in ambulatory and hospitalised patients. For an overview of the recommendations formulated by the expert panel, we refer to the key messages for clinical practice in this article.
- Published
- 2016
16. Primitive Pulmonary 'Malignant Epithelioid Hemangioendothelioma' versus Epithelioid Angiosarcoma A Case Report and Review of the Literature
- Author
-
Van de Walle H, Lebrun E, Winant C, Donfut Al, Holbrechts S, Lemaitre J, and Carlier P
- Subjects
Male ,medicine.medical_specialty ,Pathology ,Lung Neoplasms ,Lung ,business.industry ,Treatment regimen ,Hemangiosarcoma ,Epithelioid Angiosarcoma ,General Medicine ,Middle Aged ,medicine.disease ,Dermatology ,digestive system diseases ,Hemangioendothelioma ,Diagnosis, Differential ,medicine.anatomical_structure ,Hemangioendothelioma, Epithelioid ,Humans ,Medicine ,Malignant epithelioid hemangioendothelioma ,Surgery ,Angiosarcoma ,business ,neoplasms - Abstract
We describe the case of a 56-year-old man presenting a primary pulmonary epithelioid angiosarcoma versus malignant epithelioid hemangioendothelioma still alive, without recurrence at nearly two years after the beginning of the symptoms. The primary pulmonary angiosarcoma is extremely rare, being reported only in a handful of cases. Metastatic involvement of the lung (90%) is far more common than primary pulmonary involvement (10%). Various predisposing condition for the development of angiosarcoma have been described. Early diagnosis is not common, because of the rarity of angiosarcoma in the lung and consequent low index of suspicion. Due to the paucity of cases, there are no defined treatment regimens for this entity. However, there is a tendency for surgical intervention in all reported cases.
- Published
- 2014
17. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer
- Author
-
Hendlisz, Alain, Deleporte, Amélie, Delaunoit, Thierry, Marechal, Raphaël, Peeters, Marc, Holbrechts, S., Van Den Eynde, Marc, Houbiers, Ghislain, Filleul, Bertrand, Van Laethem, Jean-Luc, Ceyssens, Sarah, Barbuto, Anna-Maria, Lhommel, Renaud, Demolin, Gauthier, Garcia, Camilo, El Mansy, Hazem, Ameye, Lieveke, Moreau, Michel, Guiot, Thomas, Paesmans, Marianne, Piccart-Gebhart, Martine, Flamen, Patrick, Santini, Daniele, UCL - (SLuc) Service de médecine nucléaire, UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre du cancer, and UCL - (SLuc) Unité d'oncologie médicale
- Subjects
Oncology ,Sorafenib ,Adult ,Male ,Niacinamide ,medicine.medical_specialty ,Pathology ,Colorectal cancer ,medicine.medical_treatment ,Psychologie appliquée ,lcsh:Medicine ,Glucose-6-Phosphate ,Disease-Free Survival ,Capecitabine ,Breast cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Humans ,Prospective Studies ,Neoplasm Metastasis ,lcsh:Science ,Aged ,Aged, 80 and over ,Chemotherapy ,Multidisciplinary ,business.industry ,Phenylurea Compounds ,lcsh:R ,Sciences bio-médicales et agricoles ,Middle Aged ,medicine.disease ,Radiography ,Survival Rate ,Positron-Emission Tomography ,Toxicity ,Biomarker (medicine) ,lcsh:Q ,Female ,business ,Colorectal Neoplasms ,Engineering sciences. Technology ,Biologie ,Drug metabolism ,medicine.drug ,Research Article - Abstract
Background Tumoral heterogeneity is a major determinant of resistance in solid tumors. FDG-PET/CT can identify early during chemotherapy non-responsive lesions within the whole body tumor load. This prospective multicentric proof-of-concept study explores intra-individual metabolic response (mR) heterogeneity as a treatment efficacy biomarker in chemorefractory metastatic colorectal cancer (mCRC). Methods Standardized FDG-PET/CT was performed at baseline and after the first cycle of combined sorafenib (600mg/day for 21 days, then 800mg/day) and capecitabine (1700 mg/m2/day administered D1-14 every 21 days). MR assessment was categorized according to the proportion of metabolically non-responding (non-mR) lesions (stable FDG uptake with SUV-max decrease, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2015
18. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer
- Author
-
Woff, Erwin, Hendlisz, Alain, Garcia, Camilo, Deleporte, Amélie, Delaunoit, Thierry, Marechal, Raphaël, Holbrechts, S., Van Den Eynde, Marc, Demolin, Gauthier, Vierasu, Irina, Lhommel, Renaud, Gauthier, Namur, Guiot, Thomas, Ameye, Lieveke, Flamen, Patrick, Woff, Erwin, Hendlisz, Alain, Garcia, Camilo, Deleporte, Amélie, Delaunoit, Thierry, Marechal, Raphaël, Holbrechts, S., Van Den Eynde, Marc, Demolin, Gauthier, Vierasu, Irina, Lhommel, Renaud, Gauthier, Namur, Guiot, Thomas, Ameye, Lieveke, and Flamen, Patrick
- Abstract
Introduction: The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, thereby impairing the correlation between the absence of tumour shrinkage and the patient’s unlikelihood of benefit. The aim of the study was to assess the predictive value of early metabolic response (mR) evaluation after one cycle, and its interlesional heterogeneity to a later metabolic and morphological response assessment performed after three cycles in metastatic colorectal cancer (mCRC) patients treated with combined sorafenib and capecitabine. Methods: This substudy was performed within the framework of a wider prospective multicenter study on the predictive value of early FDG PET-CT response assessment (SoMore study). A lesion-based response analysis was performed, including all measurable lesions identified on the baseline PET. On a per-patient basis, a descriptive 4-class response categorization was applied based upon the presence and proportion of non-responding lesions. For dichotomic response comparison, all patients with at least one resistant lesion were classified as non-responding. Results: On baseline FDG PET-CT, 124 measurable “target” lesions were identified in 38 patients. Early mR assessments showed 18 patients (47 %) without treatment resistant lesions and 12 patients (32 %) with interlesional response heterogeneity. The NPV and PPV of early mR were 85 % (35/41) and 84 % (70/83), respectively, on a per-lesion basis and 95 % (19/20) and 72 % (13/18), respectively, on a dichotomized per-patient basis. Conclusions: Early mR assessment performed after one cycle of sorafenib-capecitabine in mCRC is highly predictive of non-response at a standard response assessment time. The high NPV (95 %) of early mR could be useful as the basis for early treatment discontinuation or adaptation to spare patients from ex, SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2016
19. Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy
- Author
-
Machiels, Jean Pascal, Boegner, Petra, Brohée, Dany, Quanter, Didierde, Louviaux, Ingrid, Sautois, Brieuc, Whenham, Nicolas, Berchem, Guy, Vanderschueren, Bernadette, Fontaine, Christel, Schmitz, Sandra, Vanmaanen, Aline, Gillain, Aline, Schoonjans, Joelle, Rottey, Sylvie, Vandenbulcke, Jean Marie, Filleul, Bertrand, Seront, Emmanuel, Henry, Stéphanie, D'Hondt, Lionel, Lonchay, Christophe, Holbrechts, S., Machiels, Jean Pascal, Boegner, Petra, Brohée, Dany, Quanter, Didierde, Louviaux, Ingrid, Sautois, Brieuc, Whenham, Nicolas, Berchem, Guy, Vanderschueren, Bernadette, Fontaine, Christel, Schmitz, Sandra, Vanmaanen, Aline, Gillain, Aline, Schoonjans, Joelle, Rottey, Sylvie, Vandenbulcke, Jean Marie, Filleul, Bertrand, Seront, Emmanuel, Henry, Stéphanie, D'Hondt, Lionel, Lonchay, Christophe, and Holbrechts, S.
- Abstract
Background. Cabazitaxel is a second-generation taxane that improves the survival of patients with metastatic castrate-resistant prostate cancer following docetaxel therapy. Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. In this randomized phase II trial, we investigated cabazitaxel in patients with recurrent SCCHN. Methods. Patients with incurable SCCHN with progression after platinum-based therapy were randomly assigned to cabazitaxel every 3 weeks (cycle 1, 20 mg/m2, increased to 25 mg/m2 for subsequent cycles in the absence of nonhematological adverse events [AEs] greater than grade 2 and hematological AEs greater than grade 3) or methotrexate (40 mg/m2/week). The patients were stratified according to their performance status and previous platinum-based chemotherapy for palliation versus curative intent. The primary endpoint was the progression-free survival rate (PFSR) at 18 weeks. Results. Of the 101 patients, 53 and 48, with a median age of 58.0 years (range, 41-80), were randomly assigned to cabazitaxel or methotrexate, respectively. The PFSR at 18 weeks was 13.2% (95% confidence interval [CI], 5%-25%) for cabazitaxel and 8.3% (95% CI, 2%-20%) for methotrexate. The median progression-free survival was 1.9 months in both arms. The median overall survival was 5.0 and 3.6 months for cabazitaxel and methotrexate, respectively. More patients experienced serious adverse events with cabazitaxel than with methotrexate (54% vs. 36%). The most common drug-related grade 3-4 AE in the cabazitaxel arm was febrile neutropenia (17.3%). Conclusion. This study did not meet its primary endpoint. Cabazitaxel has low activity in recurrent SCCHN., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2016
20. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: Proof of concept
- Author
-
Van Den Heuvel, Bert, Delaunoit, Thierry, Monsaert, Els, Vanderstraeten, Erik, Van Laethem, Jean-Luc, Lybaert, Willem, Holbrechts, S., Rolfo, Christian, Peeters, Michel, Hendlisz, Alain, Van Den Eynde, Marc, Machiels, Godelieve, Deroux, Isabelle, Geboes, Karen, Deman, Marc, Hendrickx, Koen, Van Den Heuvel, Bert, Delaunoit, Thierry, Monsaert, Els, Vanderstraeten, Erik, Van Laethem, Jean-Luc, Lybaert, Willem, Holbrechts, S., Rolfo, Christian, Peeters, Michel, Hendlisz, Alain, Van Den Eynde, Marc, Machiels, Godelieve, Deroux, Isabelle, Geboes, Karen, Deman, Marc, and Hendrickx, Koen
- Abstract
BACKGROUND: The aim of this study is to investigate the role of octreotide long-acting release (LAR) in secondary prevention in patients with chemotherapy-induced diarrhea. METHODS: In this study, patients experiencing CID ≥ grade 2 received 30 mg long-acting octreotide as a monthly injection and the next chemotherapy dose was administrated with a 25% dose decrease. If no CID ≥ grade 2 occurred, subsequent chemotherapy doses were increased to the initial 100% values. The primary endpoint of the study was the diarrhea control rate (< grade 2) for patients receiving the optimal dose of chemotherapy for a minimum of 2 cycles. RESULTS: Twenty-nine patients were included. Ten patients experienced no improvement or ended the study very early after the first injection of octreotide LAR. Nineteen patients had a reduction in the grade of diarrhea after the first administration of octreotide LAR and a reduced chemotherapy dose. Seven of them (24%) did not reach the end of the study because of disease progression (6) or lost to follow-up (1). Ultimately, 12 patients (41%) continued the study till the end. In ten of these twelve patients, there was a significant and persisting reduction of diarrhea while receiving full-dose chemotherapy. CONCLUSIONS: This study suggests that monthly injections with long-acting octreotide might be used as a secondary prevention of chemotherapy-induced diarrhea. Its usefulness and optimal dosage in secondary prevention in combination with antidiarrheal agents needs further research., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2016
21. Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design
- Author
-
Paesmans, Marianne, Danyi, Sophie, Pasleau, Françoise, Ameye, Lieveke, Van Meerhaeghe, Alain, Sculier, Jean-Paul, Grigoriu, Bogdan, Ocak, Sebahat, Roelandts, Martine, Lafitte, Jean-Jacques, Holbrechts, S., Berghmans, Thierry, Meert, Anne-Pascale, Moretti, Luigi, Paesmans, Marianne, Danyi, Sophie, Pasleau, Françoise, Ameye, Lieveke, Van Meerhaeghe, Alain, Sculier, Jean-Paul, Grigoriu, Bogdan, Ocak, Sebahat, Roelandts, Martine, Lafitte, Jean-Jacques, Holbrechts, S., Berghmans, Thierry, Meert, Anne-Pascale, and Moretti, Luigi
- Abstract
The use of noninferiority randomised trials for patients with advanced non-small cell lung cancer has emerged during the past 10-15 years but has raised some issues related to their justification and methodology. The present systematic review aimed to assess trial characteristics and methodological aspects. All randomised clinical trials with a hypothesis of noninferiority/equivalence, published in English, were identified. Several readers extracted a priori defined methodological information. A qualitative analysis was then performed. We identified 20 randomised clinical trials (three phase II and 17 phase III), 11 of them being conducted in strong collaboration with industry. We highlighted some deficiencies in the reports like the lack of justification for both the noninferiority assumption and the definition of the noninferiority margin, as well as inconsistencies between the results and the authors' conclusions. CONSORT guidelines were better followed for general items than for specific items (p<0.001). Improvement in the reporting of the methodology of noninferiority/equivalence trials is needed to avoid misleading interpretation and to allow readers to be fully aware of the assumptions underlying the trial designs. They should be restricted to limited specific situations with a strong justification why a noninferiority hypothesis is acceptable., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2015
22. Surrogate markers predicting overall survival for lung cancer : elcwp recommendations
- Author
-
Berghmans , T., Pasleau , F., Paesmans , M., Bonduelle , Y., Cadranel , J., Cs Toth , I., Garcia , C., Giner , V., Holbrechts , S., Lafitte , J. J., Lecomte , J., Louviaux , I., Markiewicz , E., Meert , A. P., Richez , M., Roelandts , M., Scherpereel , A., Tulippe , Ch, Van Houtte , P., Van Schil , P., Wachters , C., Westeel , V., Sculier , J. P., Renseigné , Non, Museu Nacl Hist Nat, Université de Lisbonne, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Subjects
Oncology ,Lung Neoplasms ,medicine.medical_treatment ,Medical Oncology ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,Carcinoma, Non-Small-Cell Lung ,MESH : Tumor Markers, Biological ,Pulmonary Medicine ,030212 general & internal medicine ,MESH: Treatment Outcome ,MESH: Medical Oncology ,MESH : Evidence-Based Medicine ,Evidence-Based Medicine ,Respiratory disease ,MESH: Guidelines as Topic ,3. Good health ,Europe ,Treatment Outcome ,030220 oncology & carcinogenesis ,MESH : Disease-Free Survival ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,MESH : Europe ,MEDLINE ,Guidelines as Topic ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,MESH : Treatment Outcome ,Disease-Free Survival ,03 medical and health sciences ,MESH : Medical Oncology ,Internal medicine ,Biomarkers, Tumor ,medicine ,Carcinoma ,Overall survival ,Humans ,MESH : Lung Neoplasms ,Lung cancer ,MESH: Pulmonary Medicine ,MESH : Guidelines as Topic ,MESH : Pulmonary Medicine ,MESH: Humans ,MESH : Carcinoma, Non-Small-Cell Lung ,business.industry ,MESH : Humans ,MESH: Biological Markers ,Cancer ,Evidence-based medicine ,medicine.disease ,Surgery ,MESH: Lung Neoplasms ,respiratory tract diseases ,Radiation therapy ,MESH : Biological Markers ,MESH: Tumor Markers, Biological ,MESH: Disease-Free Survival ,MESH: Europe ,Human medicine ,business ,Biomarkers ,MESH: Carcinoma, Non-Small-Cell Lung ,MESH: Evidence-Based Medicine - Abstract
International audience; The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers), instead of survival, in determining treatment efficacy in patients with lung cancer. Initially, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine questions were then formulated by the ELCWP. After reviewing the literature with experts on these questions, it can be concluded that overall survival is still the best criterion for predicting treatment efficacy in lung cancer. Some intermediate criteria can be early predictors, if not surrogates, for survival, despite limitations in their potential application: these include time to progression, progression-free survival, objective response, local control after radiotherapy, downstaging in locally advanced nonsmall cell lung cancer (NSCLC), complete resection and pathological TNM in resected NSCLC, and a few circulating markers. Other criteria assessed in these recommendations are not currently adequate surrogates of survival in lung cancer.
- Published
- 2011
23. Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC) and measurable soft tissue disease
- Author
-
Smith, D.c., Spira, A., De Grève, Jacques, Hart, L., Holbrechts, S., Lin, C.c., Hussain, M., Herrick, S., Houggy, K., Vogelzang, N., and Laboratory of Molecular and Medical Oncology
- Subjects
Prostate cancer ,Soft tissue - Abstract
No abstract available
- Published
- 2010
24. Regorafenib assesment guided by metabolic imaging in refractory advanced colorectal cancer (ACRC) : REGARD-C study
- Author
-
UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service de psychiatrie adulte, UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Hendlisz, A, Deleporte, A, Delaunoit, T, Peeters, M, Demolin, G, Janssens , J, Holbrechts, S, Maréchal, R, Carrasco Bertrand, Javier, Van Den Eynde, M, Geboes, KP, Goeminne, JC, D'Hondt, Lionel, Paesmans, M, Vandeputte, C, Hoerner, F, Flamen, P, 50th annual meeting science & society - ASCO, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Service de psychiatrie adulte, UCL - (MGD) Service d'oncologie médicale, UCL - SSS/IREC/MONT - Pôle Mont Godinne, Hendlisz, A, Deleporte, A, Delaunoit, T, Peeters, M, Demolin, G, Janssens , J, Holbrechts, S, Maréchal, R, Carrasco Bertrand, Javier, Van Den Eynde, M, Geboes, KP, Goeminne, JC, D'Hondt, Lionel, Paesmans, M, Vandeputte, C, Hoerner, F, Flamen, P, and 50th annual meeting science & society - ASCO
- Published
- 2014
25. Guidelines of clinical practice made by the European Lung Cancer Working Party: Updates [Les recommandations de pratique clinique de l'European Lung Cancer Working Party: Mises a Ì jour]
- Author
-
Berghmans, Thierry, Cortot, A., CsToth, Ingrid, Garcia, Camillo, Giner, Vicente, Grigoriu, Bogdan, Holbrechts, S., Lafitte, Jean-Jacques, Meert, Anne-Pascale, Moretti, Luigi, Paesmans, M., Remmelink, Myriam, Richez, Michel, Roelandts, Martine, Scherpereel, Arnaud, Tulippe, Christian, Van Houtte, Paul, Sculier, Jean-Paul, Berghmans, Thierry, Cortot, A., CsToth, Ingrid, Garcia, Camillo, Giner, Vicente, Grigoriu, Bogdan, Holbrechts, S., Lafitte, Jean-Jacques, Meert, Anne-Pascale, Moretti, Luigi, Paesmans, M., Remmelink, Myriam, Richez, Michel, Roelandts, Martine, Scherpereel, Arnaud, Tulippe, Christian, Van Houtte, Paul, and Sculier, Jean-Paul
- Abstract
info:eu-repo/semantics/published
- Published
- 2014
26. Weekly Versus Biweekly Combination of Docetaxel (D)-Cisplatin (C)-5Fu (F) in Advanced Gastric Cancer and Esogastric Junction Adenocarcinoma (Agc): Doge Study
- Author
-
Deleporte, A., primary, Eynde, M. van den, additional, Forget, F., additional, Holbrechts, S., additional, Delaunoit, T., additional, Houbiers, G., additional, Kalantari, H. Rezaei, additional, Laurent, S., additional, Vanderstraeten, E., additional, De Man, M., additional, Vergauwe, P., additional, Clausse, M., additional, Vanderauwera, J., additional, Pierre, P., additional, D'Hondt, L., additional, Ghillemijn, B., additional, Covas, A., additional, Paesmans, M., additional, Ameye, L., additional, and Hendlisz, A., additional
- Published
- 2014
- Full Text
- View/download PDF
27. Primitive Pulmonary “Malignant Epithelioid Hemangioendothelioma” versus Epithelioid Angiosarcoma A Case Report and Review of the Literature
- Author
-
Donfut, A.-L., primary, Lemaitre, J., additional, Walle, H. Van de, additional, Holbrechts, S., additional, Carlier, P., additional, Winanf, C., additional, and Lebrun1, E., additional
- Published
- 2014
- Full Text
- View/download PDF
28. A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer
- Author
-
Berghmans, Thierry, Van Houtte, Paul, Paesmans, Marianne, Giner, Vicente, Lecomte, J., Koumakis, George, Richez, Michel, Holbrechts, S., Roelandts, Martine, Meert, Anne-Pascale, Alard, Serge, Leclercq, Nathalie, Sculier, Jean-Paul, Berghmans, Thierry, Van Houtte, Paul, Paesmans, Marianne, Giner, Vicente, Lecomte, J., Koumakis, George, Richez, Michel, Holbrechts, S., Roelandts, Martine, Meert, Anne-Pascale, Alard, Serge, Leclercq, Nathalie, and Sculier, Jean-Paul
- Abstract
As concomitant chemoradiotherapy for stage III NSCLC is associated with survival advantage in comparison to a sequential approach, we conducted a phase III randomised study aiming to determine the best sequence and safety of chemotherapy (CT) and chemoradiotherapy (CT-RT), using a regimen with cisplatin (CDDP), gemcitabine (GEM) and vinorelbine (VNR). Unresectable stage III NSCLC patients received CDDP (60 mg/m2), GEM (1 g/m2, days 1 and 8) and VNR (25 mg/m2, days 1 and 8) with reduced dosage of GEM and VNR during radiotherapy (66 Gy). Two cycles of CT with radiotherapy followed by two further cycles of CT alone were administered in arm A or the reverse sequence in arm B. The study was prematurely closed for poor accrual due to administrative problems. Forty-nine eligible patients were randomised. Response rates and median survival times were, respectively 57% (95% CI: 36-78%) and 17 months (95% CI: 9.3-24.6 months) in arm A and 79% (95% CI: 64-94%) and 23.9 months (95% CI: 13.3-34.5 months) in arm B (p > 0.05). Chemotherapy dose-intensity was significantly reduced in arm A. Grade 3-4 oesophagitis occurred in 5 patients. One case of grade 5 radiation pneumonitis was observed. In conclusion, chemoradiotherapy with CDDP, GEM and VNR appears feasible as initial treatment or after induction chemotherapy. Consolidation chemoradiotherapy seems less toxic with a better observed response rates and survival although no valid conclusion can be drawn from the comparison of both arms. © 2008 Elsevier Ireland Ltd. All rights reserved., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2009
29. Somore Trial: Combining Sorafenib (SOR) with Capecitabine (CAP) Yields Highly Encouraging Survival Results and Elevated Metabolic Response Rate in Chemorefractory Metastatic Colorectal Cancer (MCRC)
- Author
-
Deleporte, A., primary, Hendlisz, A., additional, Delaunoit, T., additional, Marechal, R., additional, Peeters, M., additional, Holbrechts, S., additional, van den Eynde, M., additional, Houbiers, G., additional, Moreau, M., additional, and Flamen, P., additional
- Published
- 2012
- Full Text
- View/download PDF
30. 406 Phase 2 study of XL184 in a cohort of patients (pts) with castration resistant prostate cancer (CRPC) and measurable soft tissue disease
- Author
-
Smith, D.C., primary, Spira, A., additional, Grève, J. De, additional, Hart, L., additional, Holbrechts, S., additional, Lin, C.C., additional, Hussain, M., additional, Herrick, S., additional, Houggy, K., additional, and Vogelzang, N., additional
- Published
- 2010
- Full Text
- View/download PDF
31. P-194 A feasibility study preparing to a phase III randomised trialcomparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer. A trial conducted by the European Lung Cancer Working Party (ELCWP)
- Author
-
Berghmans, T., primary, Sculier, J., additional, Recloux, P., additional, Van Cutsem, O., additional, Efremidis, A., additional, Holbrechts, S., additional, Roelandts, M., additional, Fraikin, J., additional, Ninane, V., additional, and Van Houtte, P., additional
- Published
- 2005
- Full Text
- View/download PDF
32. 624P - Weekly Versus Biweekly Combination of Docetaxel (D)-Cisplatin (C)-5Fu (F) in Advanced Gastric Cancer and Esogastric Junction Adenocarcinoma (Agc): Doge Study
- Author
-
Deleporte, A., Eynde, M. van den, Forget, F., Holbrechts, S., Delaunoit, T., Houbiers, G., Kalantari, H. Rezaei, Laurent, S., Vanderstraeten, E., De Man, M., Vergauwe, P., Clausse, M., Vanderauwera, J., Pierre, P., D'Hondt, L., Ghillemijn, B., Covas, A., Paesmans, M., Ameye, L., and Hendlisz, A.
- Published
- 2014
- Full Text
- View/download PDF
33. O-003 - Exploratory analysis based on tumor location of REACHIN, a randomized, double-blinded, placebo-controlled phase 2 trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for advanced/metastatic biliary tract tumors.
- Author
-
Demols, A., Borbath, I., Van den Eynde, M., Houbiers, G., Peeters, M., Marechal, R., Delaunoit, T., Goeminne, J., Laurent, S., Holbrechts, S., Paesmans, M., and Van Laethem, J.
- Subjects
- *
BILIARY tract , *REGORAFENIB , *GEMCITABINE , *CANCER chemotherapy , *METASTASIS - Published
- 2019
- Full Text
- View/download PDF
34. BrainStorm: a multicenter international study to tackle CNS metastases in solid tumors.
- Author
-
Martins-Branco D, Nader-Marta G, Gombos A, Barthelemy P, Goncalves A, Borcoman E, Clatot F, Holbrechts S, De Maio D'Esposito E, Cheymol C, Vanhaudenarde V, Duhoux FP, Duhem C, Decoster L, Denys H, Lefranc F, Canon JL, Clement PM, Gligorov J, Paesmans M, Kindt N, Awada A, and Kotecki N
- Subjects
- Humans, Central Nervous System Neoplasms secondary, Brain Neoplasms secondary
- Published
- 2023
- Full Text
- View/download PDF
35. Circulating DNA in the neoadjuvant setting of early stage colon cancer.
- Author
-
Bregni G, Pretta A, Senti C, Acedo Reina E, Vandeputte C, Trevisi E, Gkolfakis P, Kehagias P, Deleporte A, Van Laethem JL, Vergauwe P, Van den Eynde M, Deboever G, Janssens J, Demolin G, Holbrechts S, Clausse M, De Grez T, Peeters M, D'Hondt L, Geboes K, Besse-Hammer T, Rothé F, Flamen P, Hendlisz A, and Sclafani F
- Subjects
- Humans, Neoadjuvant Therapy, Prognosis, Biomarkers, Tumor genetics, Cell-Free Nucleic Acids, Circulating Tumor DNA genetics, Colonic Neoplasms drug therapy, Colonic Neoplasms genetics, Colonic Neoplasms surgery
- Abstract
Background: While circulating tumour (ct)DNA is an indicator of minimal residual disease and negative prognostic factor in stage II-III colon cancer, no study has ever analysed the value of this biomarker in colon cancer patients treated with neoadjuvant chemotherapy. We sought to fill this gap by using prospectively collected plasma samples from 80 stage III colon cancer patients, receiving one cycle of neoadjuvant FOLFOX followed by surgery +/- adjuvant FOLFOX in the PePiTA trial., Material and Methods: Samples were collected at baseline, 2 weeks and surgery. NPY and WIF1 were selected as universal methylation markers for ctDNA, and analysed with ddPCR technology. ROC curves were applied for cut-off points, and outcome measures included 5-year disease-free survival (DFS) and 6-year overall survival (OS)., Results: After a median follow-up of 52.5 months, baseline circulating-free (cf) DNA was an independent prognostic factor for DFS (HR 3.35, 95% CI: 1.15-9.77, p = .03), and a trend towards a similar association was observed for relative cfDNA changes between baseline and surgery (HR 2.57, 95% CI: 0.94-7.05, p = .07). Among 60 ctDNA assessable patients, 25 (42%) had detectable ctDNA at baseline. While detection of ctDNA at any pre-operative timepoint was not associated with outcome, patients with ctDNA increase (change of the worst trending methylation marker ≥11%, or mean ctDNA change of NPY and WIF1 ≥ 0%) between baseline and surgery showed a trend towards worse 5-year DFS (HR 3.66, 95% CI: 0.81-16.44, p = .09)., Conclusion: This is the first study of ctDNA in the neoadjuvant setting of early-stage colon cancer. Results are hypothesis-generating and should be confirmed in larger series.
- Published
- 2022
- Full Text
- View/download PDF
36. Sex and Regorafenib Toxicity in Refractory Colorectal Cancer: Safety Analysis of the RegARd-C Trial.
- Author
-
Vandeputte C, Bregni G, Gkolfakis P, Guiot T, Pretta A, Kehagias P, Senti C, Reina EA, Van Bogaert C, Deleporte A, Geboes K, Delaunoit T, Demolin G, Peeters M, D'Hondt L, Janssens J, Carrasco J, Holbrechts S, Goeminne JC, Vergauwe P, Van Laethem JL, Flamen P, Hendlisz A, and Sclafani F
- Subjects
- Female, Humans, Male, Phenylurea Compounds adverse effects, Prospective Studies, Pyridines, Colorectal Neoplasms drug therapy, Quality of Life
- Abstract
Background: Regorafenib is a standard treatment for refractory metastatic colorectal cancer (mCRC). In view of the toxicity burden, significant research efforts have been made to increase the therapeutic ratio of this multikinase inhibitor. Predictive factors for treatment-related adverse events (TRAEs), however, are still lacking., Materials and Methods: We assessed the association between a number of baseline clinical, laboratory and imaging parameters and the occurrence of TRAEs in 136 patients who had received regorafenib (160 mg/day, 3-weeks-on/1-week-off) in a prospective phase II clinical trial., Results: Grade ≥ 2 TRAEs during the first cycle of treatment (84% vs. 60%, P = .002) and grade ≥ 3 TRAEs throughout the whole treatment (71% vs. 53%, P = .035) occurred more frequently in females, with sex being the only independent predictive factor of early and any-time toxicity (OR 3.4; 95% CI: 1.2-11.1, P = .02 and OR 2.1; 95% CI: 1.0-4.4, P = .045, respectively). Fatigue, anorexia, hypertension, and rash were reported significantly more frequently by females than males (P < .04). Females were also more likely to suffer early (19% vs. 5%, P = .014) and any-time serious AEs (28% vs. 9%, P = .005), and to require early dose modifications (55% vs. 37%, P = .055)., Conclusion: This is the first study showing an association between sex and TRAEs during regorafenib treatment for mCRC. If confirmed in larger, independent series, these results could pave the way for the implementation of personalized regorafenib dosing strategies with the potential to optimize oncological outcomes while reducing toxicity and preserving quality of life., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. Critically ill cancer patient's resuscitation: a Belgian/French societies' consensus conference.
- Author
-
Meert AP, Wittnebel S, Holbrechts S, Toffart AC, Lafitte JJ, Piagnerelli M, Lemaitre F, Peyrony O, Calvel L, Lemaitre J, Canet E, Demoule A, Darmon M, Sculier JP, Voigt L, Lemiale V, Pène F, Schnell D, Lengline E, Berghmans T, Fiévet L, Jungels C, Wang X, Bold I, Pistone A, Salaroli A, Grigoriu B, and Benoit D
- Subjects
- Belgium, Critical Care, Humans, Intensive Care Units, Respiration, Artificial, Systematic Reviews as Topic, Critical Illness, Neoplasms therapy
- Abstract
To respond to the legitimate questions raised by the application of invasive methods of monitoring and life-support techniques in cancer patients admitted in the ICU, the European Lung Cancer Working Party and the Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique, set up a consensus conference. The methodology involved a systematic literature review, experts' opinion and a final consensus conference about nine predefined questions1. Which triage criteria, in terms of complications and considering the underlying neoplastic disease and possible therapeutic limitations, should be used to guide admission of cancer patient to intensive care units?2. Which ventilatory support [High Flow Oxygenation, Non-invasive Ventilation (NIV), Invasive Mechanical Ventilation (IMV), Extra-Corporeal Membrane Oxygenation (ECMO)] should be used, for which complications and in which environment?3. Which support should be used for extra-renal purification, in which conditions and environment?4. Which haemodynamic support should be used, for which complications, and in which environment?5. Which benefit of cardiopulmonary resuscitation in cancer patients and for which complications?6. Which intensive monitoring in the context of oncologic treatment (surgery, anti-cancer treatment …)?7. What specific considerations should be taken into account in the intensive care unit?8. Based on which criteria, in terms of benefit and complications and taking into account the neoplastic disease, patients hospitalized in an intensive care unit (or equivalent) should receive cellular elements derived from the blood (red blood cells, white blood cells and platelets)?9. Which training is required for critical care doctors in charge of cancer patients?, (© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
38. Antiphospholipid syndrome-induced ischemic stroke following pembrolizumab: Case report and systematic review.
- Author
-
Tota V, Dagonnier M, Wery D, Binet L, Nagy N, Durieux V, Diaz M, Elosegi JA, and Holbrechts S
- Subjects
- Aged, Humans, Male, Antibodies, Monoclonal, Humanized adverse effects, Antiphospholipid Syndrome complications, Antiphospholipid Syndrome diagnosis, Brain Ischemia diagnosis, Brain Ischemia etiology, Carcinoma, Non-Small-Cell Lung drug therapy, Ischemic Stroke diagnosis, Ischemic Stroke etiology, Lung Neoplasms drug therapy
- Abstract
Immune checkpoint inhibitors (ICI) improve the prognosis of patients with advanced non-small cell lung cancer. However, clinicians should be aware of potentially life-threatening immune-related adverse events (irAEs). We report a case of a 67-year-old man with lung adenocarcinoma who developed an acute ischemic stroke after the second administration of pembrolizumab. The patient benefited from thrombolysis and mechanical thrombectomy with improved neurological outcome. An anti-phospholipid syndrome (APS) was diagnosed. Simultaneously, he developed a grade IV autoimmune hepatitis. Bothmanifestations were considered irAEs and the ICI treatment was discontinued. Steroids were initiated resulting in irAEs resolution. Remarkably, the patient achieved a complete oncological response and persistent remission after one year follow-up despite early discontinuation of pembrolizumab. Of note, APS is rarely reported as irAE. To our knowledge, this is the first case reported in the context of lung cancer. A systematic review of the literature is provided., (Copyright © 2021. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
39. Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
- Author
-
Deleporte A, Van den Eynde M, Forget F, Holbrechts S, Delaunoit T, Houbiers G, Kalantari HR, Laurent S, Vanderstraeten E, De Man M, Vergauwe P, Clausse M, Van Der Auwera J, D'Hondt L, Pierre P, Ghillemijn B, Covas A, Paesmans M, Ameye L, Awada A, Sclafani F, and Hendlisz A
- Subjects
- Adenocarcinoma mortality, Adenocarcinoma pathology, Adult, Aged, Aged, 80 and over, Anorexia chemically induced, Anorexia epidemiology, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Cisplatin administration & dosage, Cisplatin adverse effects, Diarrhea chemically induced, Diarrhea epidemiology, Docetaxel administration & dosage, Docetaxel adverse effects, Drug Administration Schedule, Fatigue chemically induced, Fatigue epidemiology, Febrile Neutropenia epidemiology, Female, Fluorouracil administration & dosage, Fluorouracil adverse effects, Granulocyte Colony-Stimulating Factor, Humans, Male, Middle Aged, Neutropenia chemically induced, Neutropenia epidemiology, Progression-Free Survival, Stomach Neoplasms mortality, Stomach Neoplasms pathology, Vomiting chemically induced, Vomiting epidemiology, Adenocarcinoma drug therapy, Antineoplastic Combined Chemotherapy Protocols adverse effects, Esophagogastric Junction, Stomach Neoplasms drug therapy
- Abstract
Background: While docetaxel/cisplatin/5-fluorouracil (DCF) outperforms CF in first-line gastric adenocarcinoma, toxicity remains an issue., Methods: This multicenter phase II trial randomized chemonaïve metastatic gastric adenocarcinoma patients to fractionated weekly DCF (D 40 mg/m
2 , C 35 mg/m², F 1800 mg/m² over 24 h, on days 1 and 8 every 3 weeks, arm (1) or fortnightly DCF (D 50 mg/m2 , C 50 mg/m², F 2000 mg/m² over 48 h every 2 weeks, arm (2). Prophylactic granulocyte colony-stimulating factor (G-CSF) was not allowed. The primary endpoint was the rate of febrile neutropenia within the first six treatment weeks (early FN)., Results: A total of 106 eligible patients were recruited. The early and overall FN rates were 9.5% and 17% in arm 1, respectively, and 5.9% and 8% in arm 2, respectively. Grade ≥3 toxicities occurred in 81% of patients in arm 1 and 90% of patients in arm 2, the most common being neutropenia (33% vs. 61%), fatigue (27% vs. 25%), vomiting (21% vs. 12%), anorexia (19% vs. 18%), and diarrhea (17% vs. 10%). Median progression-free survival and overall survival were 5.1 (95% CI, 3.2-6.5) and 8.2 months (95% CI, 6.0-14.5), respectively, in arm 1 and 5.2 (95% CI, 3.0-6.9) and 11.9 months (95% CI, 7.4-15.9), respectively, in arm 2., Conclusions: Fractionated weekly and fortnightly DCF regimens are associated with a low risk of early FN, and a better hematological toxicity profile as compared to historical DCF without compromising efficacy. Both regimens offer greater convenience removing the need for systematic use of prophylactic G-CSF., (© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)- Published
- 2021
- Full Text
- View/download PDF
40. Acute appendicitis as an unusual cause of invasive ductal breast carcinoma metastasis.
- Author
-
De Pauw V, Navez J, Holbrechts S, and Lemaitre J
- Abstract
Acute appendicitis is one of the most common causes of abdominal pain at the emergency room. In rare cases, it can be caused by malignancy, even metastatic lesions from extra-abdominal neoplasia. Herein, we report a case of a 64-year-old female with a history of invasive ductal carcinoma of the breast treated by chemotherapy, surgery, radiotherapy and hormonotherapy, relapsing several years later as a bone and a pleura metastasis successfully cured by locoregional therapy and hormonal treatment. She presented with acute abdominal pain without signs of peritonitis. Abdominal computed tomodensitometry showed sign of appendicitis. Therefore, laparoscopic exploration and appendicectomy was performed. During surgery, multiple peritoneal nodules were found and harvested. Pathology showed metastatic nodules of invasive ductal breast carcinoma, including in the appendicular wall, concluding to peritoneal carcinomatosis. The postoperative course was uneventful, but the patient died 1 year later after refusing anticancer treatment., (Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2020.)
- Published
- 2020
- Full Text
- View/download PDF
41. Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.
- Author
-
Joris S, Pieters T, Sibille A, Bustin F, Jacqmin L, Kalantari HR, Surmont V, Goeminne JC, Clinckart F, Pat K, Demey W, Deschepper K, Lambrechts M, Holbrechts S, Schallier D, and Decoster L
- Subjects
- Age Factors, Aged, Antineoplastic Agents, Immunological administration & dosage, Antineoplastic Agents, Immunological adverse effects, Belgium, Compassionate Use Trials, Humans, Retrospective Studies, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Nivolumab administration & dosage, Nivolumab adverse effects
- Abstract
Objectives: To compare real life effectiveness and safety of nivolumab in patients with non-small cell lung cancer (NSCLC), according to age and Eastern Cooperative Group performance status (ECOG-PS)., Methods: We performed a retrospective analysis of patients treated with nivolumab for NSCLC within a Belgian compassionate use program from July 2015 until December 2016. Safety and effectiveness were compared between patients aged ≥70 years and < 70 years and between ECOG-PS 0/1 and ≥ 2., Results: A total of 324 patients with NSCLC were included. There was no significant difference between older (≥70) and younger (<70 years) patients with regards to progression free survival (PFS) (4 months (95%CI 2.6;4.8) versus 3.7 months (95%CI 1;7), p = 0.483) and overall survival (OS) (9.3 months (95% CI 5.5;13.1 months) versus 8.4 months (95%CI 6.3; 10.5), p = 0,638). Patients with an ECOG-PS ≥2 had a significant lower median PFS and OS compared to patients with an ECOG-PS 0-1 (2.2 (95%CI 1.4; 2.9) versus 5.6 months (95%CI 4.1; 7.1), p = 0.001 and 3.4 (95%CI 2.3; 4.5) versus 11.1 months (95%CI 8.9; 13.2), p < 0.001 respectively). No significant difference in all grades or grade 3/4 adverse events (AEs) were observed between the different age groups (p = 0.526 and p = 0.603 respectively). Patients with an ECOG-PS 0/1 had significantly more all grades AEs (p = 0.009) but no difference in grade 3/4 AEs was observed (p = 0.406) compared to ECOG-PS ≥2., Conclusion: This real life retrospective study confirms that safety and effectiveness of nivolumab is similar between different age groups, but that effectiveness is driven by performance status., Competing Interests: Declaration of Competing Interest This research was funded by a grant from Bristol Meyers Squibb, Belgium. Lore Decoster received research grant from BMS, Bhoeringer Ingelheim; Travel grants from BMS, Roche en MSD; Advisory boards from MSD, Roche, Astra Zeneca. Thierry Pieters received speaker's fees from BMS during the study period., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
42. Prognostic value of adipose tissue and muscle mass in advanced colorectal cancer: a post hoc analysis of two non-randomized phase II trials.
- Author
-
Charette N, Vandeputte C, Ameye L, Bogaert CV, Krygier J, Guiot T, Deleporte A, Delaunoit T, Geboes K, Van Laethem JL, Peeters M, Demolin G, Holbrechts S, Flamen P, Paesmans M, and Hendlisz A
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Body Composition, Body Mass Index, Clinical Trials, Phase II as Topic, Colorectal Neoplasms diagnostic imaging, Colorectal Neoplasms therapy, Female, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Organ Size, Positron Emission Tomography Computed Tomography, Prognosis, Proportional Hazards Models, Tomography, X-Ray Computed, Adipose Tissue pathology, Colorectal Neoplasms mortality, Colorectal Neoplasms pathology, Muscle, Skeletal pathology
- Abstract
Background: The prognostic value of body composition in cancer patients has been widely studied during the last decade. The main finding of these studies is that sarcopenia, or skeletal muscle depletion, assessed by CT imaging correlates with a reduced overall survival (OS). By contrast, the prognostic value of fat mass remains ill-defined. This study aims to analyze the influence of body composition including both muscle mass and adipose tissue on OS in a homogeneous population of advanced colorectal cancer (CRC) patients., Methods: Among 235 patients with chemorefractory advanced CRC included in the SoMore and RegARd-C trials, body composition was assessed in 217 patients on baseline CT images. The relationship between body composition (sarcopenia, muscle density, subcutaneous and visceral fat index and density), body mass index (BMI) and OS were evaluated., Results: Patients with a higher BMI had a better OS (≥30 versus < 30, HR: 0.50; 0.33-0.76). Those with low muscle index and muscle density had an increased mortality (HR: 2.06; 1.45-2.93 and HR: 1.54; 1.09-2.18, respectively). Likewise, low subcutaneous and visceral fat index were associated with an increased risk of dying (HR: 1.63; 1.23-2.17 and 1.48; 1.09-2.02 respectively), as were a high subcutaneous and visceral adipose tissue density (HR: 1.93; 1.44-2.57 and 2.40; 1.79-3.20 respectively). In multivariate analysis, a high visceral fat density was the main predictor of poor survival., Conclusions: Our results confirm the protective role of obesity in CRC patients at an advanced stage, as well as the negative prognostic impact of muscle depletion on survival. More importantly, our data show for the first time that visceral adipose tissue density is an important prognostic factor in metastatic CRC., Trial Registration: NCT01290926 , 07/02/2011 and NCT01929616 , 28/08/2013.
- Published
- 2019
- Full Text
- View/download PDF
43. Systemic treatments for thymoma and thymic carcinoma: A systematic review.
- Author
-
Berghmans T, Durieux V, Holbrechts S, Jungels C, Lafitte JJ, Meert AP, Moretti L, Ocak S, Roelandts M, and Girard N
- Subjects
- Anthracyclines administration & dosage, Cisplatin administration & dosage, Female, Humans, Male, Neoplasm Recurrence, Local, Survival Analysis, Thymoma pathology, Thymus Neoplasms pathology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Thymoma drug therapy, Thymus Neoplasms drug therapy
- Abstract
Thymic tumours are rare diseases that for most of the cases are cured with surgery and eventually adjuvant radiotherapy. However, about 30% of patients present with advanced stage or relapsing tumours, which require administration of chemotherapy. While cisplatin-adriamycin-cyclophosphamide combination is regularly prescribed, other drugs have been assessed in the literature. Our aim is to evaluate the effectiveness (response rate) of systemic treatments, whatever the therapeutic line, including chemotherapy, targeted therapies and immunotherapies, in thymoma and thymic carcinoma, using the principles of evidence-based medicine. A systematic review was designed using the PICO system, by an experienced librarian and clinicians' experts in thoracic oncology, through the Ovid Medline system. Only phase II-IV trials and retrospective studies including at least 14 patients treated with the same regimen were considered. Articles were independently selected by at least two investigators. Fifty-five eligible articles were retrieved. Sixty% were dealing with platinum-based regimens, mainly cisplatin, and showed overall similar activity (mostly response rate above 50%) independently of the line of treatment or histological type (thymoma versus thymic carcinoma). Non-platinum based regimens included octreotide-prednisone and capecitabine-gemcitabine. Promising data of immunotherapy with antiPDL1 antibody (pembrolizumab) requires confirmation. Based on available data, the most popular and active regimens are cisplatin-anthracycline (CAP or ADOC) or cisplatin-etoposide combinations that should be recommended when considering first-line chemotherapy in thymoma or thymic carcinoma., (Copyright © 2018 Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
44. Unusual presentation of a hepatocellular carcinoma as a potential late side effect of radiotherapy in a patient treated for Wilms tumor in childhood.
- Author
-
Repullo D, Diaz M, Holbrechts S, Gomez-Galdón M, Van Gestel D, Bohlok A, Liberale G, and Donckier V
- Subjects
- Age of Onset, Carcinoma, Hepatocellular pathology, Humans, Infant, Kidney Neoplasms surgery, Liver Neoplasms pathology, Male, Middle Aged, Prognosis, Wilms Tumor surgery, Carcinoma, Hepatocellular etiology, Kidney Neoplasms radiotherapy, Liver Neoplasms etiology, Nephrectomy adverse effects, Radiotherapy, Adjuvant adverse effects, Wilms Tumor radiotherapy
- Abstract
Background: The development of a second primary tumor is a potential late side effect of radiotherapy. Particularly, an increased risk of secondary cancers, mostly of digestive or breast origin, has been observed in patients treated with high-dose radiotherapy for Wilms tumor (WT) in childhood. However, hepatocellular carcinoma (HCC) has been very rarely described as a potentially radiotherapy-induced tumor. We describe the case of a patient with an aggressive HCC 50 years after the treatment of a WT., Case Presentation: A 49-year old man, treated at the age of 6 weeks for a right WT by a right nephrectomy and adjuvant radiotherapy, presented with a right abdominal mass. Imaging demonstrated a 100-mm tumor invading the inferior segment of the right liver, the right colon and the right psoas muscle. The patient had no previous history of liver disease, nor of alcohol consumption, and hepatitis serologies were negatives. Biopsy demonstrated a poorly differentiated tumor of unknown origin. A panel of tumor markers was negative. Explorative surgery has been performed allowing en bloc R0 tumor resection, including resection of segments VI and VII of the liver, right hemicolectomy and resection of the anterior sheet of the right psoas muscle. Pathological examination revealed a poorly differentiated HCC. No signs of cirrhosis or chronic liver disease were observed in the non-tumor liver. Twenty weeks after surgery, the patient developed a multifocal tumor recurrence that was treated with intra-arterial
90 Yttrium radioembolization., Conclusion: In this case, the absence of risk factors for HCC, such as cirrhosis, viral hepatitis and chronic liver disease, highly suggests the development of HCC to be related to previous high-dose radiation therapy given for a right WT to a field involving the inferior part of the liver. This observation shows radiotherapy to/near the liver, particularly in childhood, to be a potential risk factor for HCC, stressing the need for a long-term specific follow-up in patients irradiated in childhood.- Published
- 2018
- Full Text
- View/download PDF
45. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature Part 4: Neurological paraneoplastic syndromes, involving the peripheral nervous system and the neuromuscular junction and muscles.
- Author
-
Ruelle L, Bentea G, Sideris S, El Koulali M, Holbrechts S, Lafitte JJ, Grigoriu B, Sculier C, Meert AP, Durieux V, Berghmans T, and Sculier JP
- Subjects
- Autoantibodies immunology, Autoimmune Diseases diagnosis, Autoimmune Diseases therapy, Autoimmunity, Humans, Muscles immunology, Muscles pathology, Neuromuscular Junction immunology, Neuromuscular Junction pathology, Paraneoplastic Syndromes diagnosis, Paraneoplastic Syndromes therapy, Paraneoplastic Syndromes, Nervous System complications, Paraneoplastic Syndromes, Nervous System immunology, Paraneoplastic Syndromes, Nervous System pathology, Peripheral Nervous System immunology, Peripheral Nervous System pathology, Autoimmune Diseases complications, Autoimmune Diseases immunology, Lung Neoplasms complications, Lung Neoplasms epidemiology, Paraneoplastic Syndromes complications, Paraneoplastic Syndromes immunology
- Abstract
The development of new immune treatment in oncology and particularly for lung cancer may induce new complications, particularly activation or reactivation of auto-immune diseases. In this context, a systematic review on the auto-immune paraneoplastic syndromes that can complicate lung cancer appears useful. This article is the fourth of a series of five and deals mainly with neurological paraneoplastic syndromes involving the peripheral nervous system and the neuromuscular junction and muscles., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
46. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 5: Neurological auto-antibodies, discussion, flow chart, conclusions.
- Author
-
Sculier C, Bentea G, Ruelle L, Grigoriu B, Coureau M, Gorham J, Sideris S, Holbrechts S, Lafitte JJ, Meert AP, Durieux V, Berghmans T, and Sculier JP
- Subjects
- Autoantibodies immunology, Autoimmune Diseases diagnosis, Autoimmune Diseases therapy, Autoimmunity, Humans, Muscles immunology, Muscles pathology, Neuromuscular Junction immunology, Neuromuscular Junction pathology, Paraneoplastic Syndromes diagnosis, Paraneoplastic Syndromes therapy, Paraneoplastic Syndromes, Nervous System complications, Paraneoplastic Syndromes, Nervous System immunology, Paraneoplastic Syndromes, Nervous System pathology, Peripheral Nervous System immunology, Peripheral Nervous System pathology, Autoimmune Diseases complications, Autoimmune Diseases immunology, Lung Neoplasms complications, Lung Neoplasms epidemiology, Paraneoplastic Syndromes complications, Paraneoplastic Syndromes immunology
- Abstract
The development of new immune treatment in oncology and particularly for lung cancer may induce new complications, particularly activation or reactivation of auto-immune diseases. In this context, a systematic review on the auto-immune paraneoplastic syndromes that can complicate lung cancer appears useful. This article is the last of a series of five and deals mainly with onconeural antibodies involved in neurological paraneoplastic syndromes and provides the final discussion., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
47. Autoimmune paraneoplastic syndromes associated to lung cancer: A systematic review of the literature: Part 2: Hematologic, cutaneous and vascular syndromes.
- Author
-
Holbrechts S, Gorham J, Sideris S, Meert AP, Durieux V, Berghmans T, and Sculier JP
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung complications, Female, Hematologic Diseases complications, Hematologic Diseases therapy, Humans, Immunotherapy adverse effects, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Lung Neoplasms surgery, Male, Middle Aged, Outcome Assessment, Health Care, Paraneoplastic Syndromes chemically induced, Skin Diseases complications, Skin Diseases immunology, Skin Diseases therapy, Vascular Diseases complications, Vascular Diseases immunology, Vascular Diseases therapy, Autoimmune Diseases chemically induced, Lung Neoplasms complications, Paraneoplastic Syndromes immunology
- Abstract
The development of new immune treatment in oncology and particularly for lung cancer may induce new complications, particularly activation or reactivation of auto-immune diseases. In this context, a systematic review on the auto-immune paraneoplastic syndromes associated with lung cancer appears useful. This article is the second of a series of five and deals with hematologic, cutaneous and vascular syndromes., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
48. Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy.
- Author
-
Machiels JP, Van Maanen A, Vandenbulcke JM, Filleul B, Seront E, Henry S, D'Hondt L, Lonchay C, Holbrechts S, Boegner P, Brohee D, Dequanter D, Louviaux I, Sautois B, Whenham N, Berchem G, Vanderschueren B, Fontaine C, Schmitz S, Gillain A, Schoonjans J, and Rottey S
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Female, Head and Neck Neoplasms mortality, Humans, Male, Methotrexate adverse effects, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local mortality, Squamous Cell Carcinoma of Head and Neck, Taxoids adverse effects, Antineoplastic Agents therapeutic use, Carcinoma, Squamous Cell drug therapy, Head and Neck Neoplasms drug therapy, Methotrexate therapeutic use, Neoplasm Recurrence, Local drug therapy, Taxoids therapeutic use
- Abstract
Lessons Learned: Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. For the first time, cabazitaxel was investigated in incurable patients with recurrent SCCHN. Patients were randomly assigned to cabazitaxel every 3 weeks or weekly methotrexate.This phase II study did not meet its primary endpoint.Cabazitaxel has low activity in SCCHN.The toxicity profile in this population also was not favorable owing to the high rate of febrile neutropenia observed (17%)., Background: Cabazitaxel is a second-generation taxane that improves the survival of patients with metastatic castrate-resistant prostate cancer following docetaxel therapy. Cabazitaxel has activity in squamous cell carcinoma of the head and neck (SCCHN) and taxane-resistant cell lines. In this randomized phase II trial, we investigated cabazitaxel in patients with recurrent SCCHN., Methods: Patients with incurable SCCHN with progression after platinum-based therapy were randomly assigned to cabazitaxel every 3 weeks (cycle 1, 20 mg/m
2 , increased to 25 mg/m2 for subsequent cycles in the absence of nonhematological adverse events [AEs] greater than grade 2 and hematological AEs greater than grade 3) or methotrexate (40 mg/m2 /week). The patients were stratified according to their performance status and previous platinum-based chemotherapy for palliation versus curative intent. The primary endpoint was the progression-free survival rate (PFSR) at 18 weeks., Results: Of the 101 patients, 53 and 48, with a median age of 58.0 years (range, 41-80), were randomly assigned to cabazitaxel or methotrexate, respectively. The PFSR at 18 weeks was 13.2% (95% confidence interval [CI], 5%-25%) for cabazitaxel and 8.3% (95% CI, 2%-20%) for methotrexate. The median progression-free survival was 1.9 months in both arms. The median overall survival was 5.0 and 3.6 months for cabazitaxel and methotrexate, respectively. More patients experienced serious adverse events with cabazitaxel than with methotrexate (54% vs. 36%). The most common drug-related grade 3-4 AE in the cabazitaxel arm was febrile neutropenia (17.3%)., Conclusion: This study did not meet its primary endpoint. Cabazitaxel has low activity in recurrent SCCHN., Competing Interests: of potential conflicts of interest may be found at the end of this article., (©AlphaMed Press; the data published online to support this summary is the property of the authors.)- Published
- 2016
- Full Text
- View/download PDF
49. Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
- Author
-
Woff E, Hendlisz A, Garcia C, Deleporte A, Delaunoit T, Maréchal R, Holbrechts S, Van den Eynde M, Demolin G, Vierasu I, Lhommel R, Gauthier N, Guiot T, Ameye L, and Flamen P
- Subjects
- Adult, Aged, Capecitabine administration & dosage, Colorectal Neoplasms diagnostic imaging, Female, Humans, Male, Middle Aged, Molecular Targeted Therapy methods, Niacinamide administration & dosage, Niacinamide analogs & derivatives, Phenylurea Compounds administration & dosage, Radiopharmaceuticals pharmacokinetics, Reproducibility of Results, Sensitivity and Specificity, Sorafenib, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Colorectal Neoplasms drug therapy, Colorectal Neoplasms secondary, Drug Monitoring methods, Fluorodeoxyglucose F18 pharmacokinetics, Positron Emission Tomography Computed Tomography methods
- Abstract
Introduction: The introduction of targeted drugs has had a significant impact on the approach to assessing tumour response. These drugs often induce a rapid cytostatic effect associated with a less pronounced and slower tumoural volume reduction, thereby impairing the correlation between the absence of tumour shrinkage and the patient's unlikelihood of benefit. The aim of the study was to assess the predictive value of early metabolic response (mR) evaluation after one cycle, and its interlesional heterogeneity to a later metabolic and morphological response assessment performed after three cycles in metastatic colorectal cancer (mCRC) patients treated with combined sorafenib and capecitabine., Methods: This substudy was performed within the framework of a wider prospective multicenter study on the predictive value of early FDG PET-CT response assessment (SoMore study). A lesion-based response analysis was performed, including all measurable lesions identified on the baseline PET. On a per-patient basis, a descriptive 4-class response categorization was applied based upon the presence and proportion of non-responding lesions. For dichotomic response comparison, all patients with at least one resistant lesion were classified as non-responding., Results: On baseline FDG PET-CT, 124 measurable "target" lesions were identified in 38 patients. Early mR assessments showed 18 patients (47 %) without treatment resistant lesions and 12 patients (32 %) with interlesional response heterogeneity. The NPV and PPV of early mR were 85 % (35/41) and 84 % (70/83), respectively, on a per-lesion basis and 95 % (19/20) and 72 % (13/18), respectively, on a dichotomized per-patient basis., Conclusions: Early mR assessment performed after one cycle of sorafenib-capecitabine in mCRC is highly predictive of non-response at a standard response assessment time. The high NPV (95 %) of early mR could be useful as the basis for early treatment discontinuation or adaptation to spare patients from exposure to non-effective drugs.
- Published
- 2016
- Full Text
- View/download PDF
50. Long-acting octreotide as secondary prevention of chemotherapy-induced diarrhea: proof of concept.
- Author
-
VAN DEN Heuvel B, Peeters M, Hendlisz A, VAN DEN Eynde M, Machiels G, Dero I, Geboes K, DE Man M, Hendrickx K, Delaunoit T, Monsaert E, Vanderstraten E, VAN Laethem JL, Lybaert W, Holbrechts S, and Rolfo C
- Abstract
Background: The aim of this study is to investigate the role of Octreotide LAR in secondary prevention in patients with chemotherapy-induced diarrhea., Methods: In this study, patients experiencing CID ≥ grade 2 received 30 mg long-acting octreotide as a monthly injection and the next chemotherapy dose was administrated with a 25% dose decrease. If no CID ≥ grade 2 occurred, subsequent chemotherapy doses were increased to the initial 100% values. The primary endpoint of the study was the diarrhea control rate (< grade 2) for patients receiving the optimal dose of chemotherapy for a minimum of 2 cycles., Results: Twenty-nine patients were included. Ten patients experienced no improvement or ended the study very early after the first injection of octreotide LAR. Nineteen patients had a reduction in the grade of diarrhea after the first administration of Octreotide LAR and a reduced chemotherapy dose. Seven of them (24%) did not reach the end of the study because of disease progression (6) or lost in follow-up (1). Ultimately 12 patients (41%) continued the study till the end. In ten of these twelve patients, there was a significant and persisting reduction of diarrhea while receiving full dose chemotherapy., Conclusion: This study suggests that monthly injections with long-acting octreotide might be used as a secondary prevention of chemotherapy-induced diarrhea. Its usefulness and optimal dosage in secondary prevention in combination with antidiarrheal agents needs further research.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.